Abstract
Human mesangial cells (HMC) were analyzed for their expression of 20-kDa homologous restriction factor (CD59), a glycophospholipid-anchored regulatory protein of the complement cascade. Flow cytometric analysis showed that CD59 was expressed on the HMC membrane and, following the activation of the terminal pathway complement components, CD59 expression on the HMC membrane increased. Northern blot analysis showed that CD59 mRNA levels increased by complement activation. Of interest, CD59 mRNA levels increased by soluble complement activation product, zymosan-activated C8-depleted serum, but not zymosan-activated C5-depleted serum. This effect of soluble complement activation product was due to the presence of the action of C5a. Thus, recombinant C5a increased CD59 mRNA levels. The capacity of CD59 to reinsert into rat E and inhibit C-mediated lysis was inhibited by mAb against CD59 (1F5). Metabolic labeling using [35S]cysteine showed that the molecular mass of CD59 in HMC was 20 kDa. In conclusion, CD59 is present on HMC and the expression of CD59 is controlled by at least two steps of complement activation pathway, C5 and C8.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
